PCPaul James Clark

Paul James Clark

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Paul James Clark has a total of 475 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Differing Epidemiology of Chronic Hepatitis C Infection, Treatment, and Outcomes Among Migrants and Australian‐Born Patients

    by Belaynew W. Taye, Patricia C. Valery, Simone I. Strasser, Martin Weltman, Alex J. Thompson, Miriam T. Levy, Barbara Leggett, Amany Zekry, Y. Julian Rong, Marie Sinclair, et al.

    The burden of hepatitis C virus (HCV) infection often falls disproportionately on migrant populations within high‐income countries. Differences in health literacy, language, comorbidities, and HCV genotype may influence HCV natural history. 3537 persons including 652 migrants treated for HCV infection with direct‐acting antiviral (DAA) (2016–2021) were analysed. We describe the epidemiology of HCV in migrant people compared to Australian‐born individuals and examine rates of sustained viral response (SVR), advanced liver fibrosis, cirrhosis, and all‐cause mortality. Multivariable logistic and Cox regression analyses examined differences by migrant status. At enrolment, Australian‐born patients were younger (mean 51.5 vs. 54.2 years; p < 0.001) and more likely to report injection drug use ( p = 0.011), risky alcohol use ( p < 0.001), or opioid replacement therapy ( p < 0.001). Among migrants, diabetes (13.9% vs. 10.3%; p = 0.008), hepatitis B virus (HBV) exposure (43.3% vs. 29.7%; p < 0.001), active HBV infection (3.1% vs. 1.6%; p = 0.033), and genotypes 4, 5, and 6 (18.3% vs. 6.6%; p < 0.001) was more common. Overall SVR rates were comparable ( p = 0.69), but SVR rates among migrants with cirrhosis were lower (88.2% vs. 95.2%; p = 0.002). Advanced fibrosis (24.5%), cirrhosis (35.0%), and five‐year survival did not differ by migrant status (all p > 0.05). In migrants, genotype 3 was associated with more advanced liver fibrosis (adj‐OR = 1.70, 95% CI 1.40–2.06) and cirrhosis (adj‐OR = 1.74, 95% CI 1.48–2.04; p < 0.001), relative to Australian‐born patients. Genotypes 2, 4 and 6 HCV were not associated with liver fibrosis and cirrhosis (all p > 0.05). In conclusion, migrants experienced equivalent SVR and rates of liver fibrosis and cirrhosis, and have equivalent or better survival compared to Australian‐born patients.

  • Open Access

    Hospital‐Admitted Injection‐Related Infections Among Incarcerated People Who Inject Drugs in Australia: A Retrospective Cohort Study

    by Andrew Palmer, Matthew Carter, Jeremy Yeo, Cecilia Shim, Jason Connor, Jeremy Hayllar, Gerald Holtmann, Naomi Moy, Elliott G. Playford, Naomi Runnegar, et al.

    Objectives: To characterise the clinical, microbiological and economic burden of hospital‐admitted, injection‐related infections among incarcerated people who inject drugs. Study Type: Retrospective observational cohort study. Setting: Secure unit of the Princess Alexandra Hospital, Brisbane, Australia. Participants: Adults incarcerated in Queensland prisons who were admitted to hospital with an injection‐related infection between 1 July 2019 and 30 June 2023. Main Outcome Measures: Types of injection‐related infection, microbiological findings, requirement for surgical or radiological source control, hospital length of stay and inpatient healthcare costs. Results: There were 321 hospital admissions for injection‐related infection among 265 patients, accounting for 282 unique infections. Most patients were male (241; 90.9%), with a mean age of 33 years (standard deviation [SD], 7.4 years), and 76 (28.7%) identified as First Nations. The most frequent infections were soft tissue infections (77/282; 27.3%), acute hepatitis C (64/282; 22.7%) and cellulitis (43/282; 15.2%). Surgical or radiological source control was required in 95 infections (34.0%), and infectious diseases consultation occurred in 130 infections (46.1%). Among 39 true‐positive blood cultures, Staphylococcus aureus was identified in 17 (43.6%), Burkholderia species in 10 (25.6%) and non‐tuberculous Mycobacterium species in 3 (7.7%). Among the 218 non‐acute hepatitis C infections, 50 (22.9%) were hepatitis C virus (HCV) RNA positive. Overall, HCV RNA was present in 114 of 282 infections (40.4%). The total inflation‐adjusted inpatient cost was $8.39 million, with a median cost per infection of $11,602 (interquartile range, $7426–$34,544). Conclusion: Injection‐related infections among incarcerated people who inject drugs were associated with substantial morbidity and healthcare costs in this large hospital cohort. A wide clinical spectrum was observed, including atypical pathogens, and clinically overt acute hepatitis C requiring hospital admission. These findings describe a significant burden of preventable disease in custodial settings and support the introduction of established primary prevention and harm‐reduction interventions in prisons.

  • Better adherence to components of an acute care bundle improves 90‐day mortality from acute decompensated chronic liver disease: a retrospective study

    by Andrea Huang, Andrew Palmer, Patricia C. Valery, Matthew Mickenbecker, Alex Johnston, Timothy O'SUllivan, Hayley Chen, Aidan Woodward, Mazhar Haque, Paul J. Clark

    Aim: To evaluate whether adherence to an acute care bundle (ACB) for decompensated cirrhosis is associated with improved patient outcomes, including 90‐day mortality, in an Australian tertiary hospital setting. Methods: This retrospective cohort study included all patients admitted with decompensated cirrhosis between June 2016 and March 2018 at a tertiary metropolitan teaching hospital. ACB adherence was assessed among six domains during the first 24 h of admission. Outcomes included in‐hospital, 30‐ and 90‐day mortality, hospital readmission and long‐term survival. Results: A total of 157 admissions from 85 patients were included. Median follow‐up was 7 years, during which the overall mortality rate reached 74%. Short‐term (30‐day) mortality was not significantly associated with ACB adherence. However, 90‐day mortality was significantly lower in patients with ≥70% adherence (13.8% vs 25.4%, P < 0.05) and ≥80% adherence (9.7% vs 25.9%, P < 0.01), independent of Model for End‐Stage Liver Disease (MELD) score, Child‐Pugh class or admitting team. No significant differences were observed in readmission rates or long‐term survival. Conclusion: Greater adherence to ACB components in the first 24 h of admission was associated with improved 90‐day mortality in patients with decompensated cirrhosis, regardless of disease severity or admitting service. These findings support the use of the ACB as a pragmatic quality improvement tool. Prospective validation is warranted.


  • Open Access

    Cause‐specific mortality among Queensland people with cirrhosis, by cirrhosis aetiology and decompensation status, 2007–22: a retrospective cohort study

    by Vikas Bhasker, Jessica R Fong, Paul J Clark, Gunter F Hartel, Richard Skoien, James O’bEirne, Elizabeth E Powell, Patricia C Valery

    Objective: To determine the cumulative incidence of overall and cause‐specific mortality among Queensland residents admitted to hospital with cirrhosis during 2007–22, by cirrhosis aetiology. Study design: Retrospective cohort study; analysis of linked Queensland Hospital Admitted Patient Data Collection and Queensland Registry of Births, Deaths and Marriages data. Setting, participants: Adult Queensland residents (18 years or older) admitted to Queensland hospitals with cirrhosis during 1 July 2007 – 31 December 2022. Main outcome measures: Ten‐year mortality, all‐cause and cause‐specific (liver‐related, extrahepatic cancer, cardiovascular disease), by cirrhosis aetiology. Results: A total of 22 525 people were followed for a median of 6.9 years (interquartile range, 3.5–11.1 years). Their mean age at the index admission with cirrhosis was 61.2 years (standard deviation, 13.0 years), 14 895 were men (66.1%), and the most frequent causes of cirrhosis were alcohol use (9550 people, 42.4%), metabolic dysfunction‐associated steatotic liver disease (MASLD; 5108 people, 22.7%), and chronic hepatitis C virus (HCV) infection (4780 people, 21.2%). A total of 12 387 people (55.0%) had died by 31 December 2022; overall mortality among people with alcohol‐related cirrhosis was 57.9%, with MASLD cirrhosis 52.1%, and with HCV‐related cirrhosis 51.6%. The proportions of deaths attributed to liver disease were larger for people who experienced decompensation during follow‐up than those who did not (alcohol‐related cirrhosis: 2538 of 3890 deaths [65.2%] v 523 of 1637 [31.9%]; HCV‐related cirrhosis: 1158 of 1714 deaths [67.6%] v 331 of 753 [44.0%]). Ten‐year liver‐related mortality was highest among people with alcohol‐related cirrhosis (48.8%; 95% confidence interval [CI], 47.2–50.4%) or HCV‐related cirrhosis (44.3%; 95% CI, 42.3–46.3%); ten‐year extrahepatic cancer mortality (18.8%; 95% CI, 16.8–20.9%) and cardiovascular disease mortality (15.6%; 95% CI, 13.8–17.7%) were highest among people with MASLD cirrhosis. In multivariable competing risks regression analyses, people with MASLD cirrhosis were less likely than people with alcohol‐related cirrhosis to die of liver disease (adjusted subdistribution hazard ratio [sHR], 0.55; 95% CI, 0.51–0.60) and more likely to die of extrahepatic cancer (adjusted sHR, 1.21; 95% CI, 1.04–1.41). Conclusions: Mortality among people who have been hospitalised with cirrhosis is high, and there is substantial variation in cause‐specific mortality by cirrhosis aetiology. Care for these patients could be improved by identifying chronic liver disease earlier, and by treating cardiovascular disease and extrahepatic malignancies in people with MASLD.


  • Glycogenic hepatopathy associated with hepatic steatosis in type 1 diabetes

    by Stephanie Teasdale, Xin Dong, Alison Griffin, Paul James Clark, Janelle Nisbet, Adam Morton, Liza Phillips, Mitchell Anthony Sullivan, Graham Galloway


  • Open Access

    Overcoming disparities in hepatocellular carcinoma outcomes in First Nations Australians: a strategic plan for action

    by Jessica Howell, Troy Combo, Paula Binks, Kylie Bragg, Sarah Bukulatjpi, Kirsty Campbell, Paul J Clark, Melissa Carroll, Jane Davies, Teresa de Santis, et al.


  • Rising hospital admissions for alcohol-related cirrhosis and the impact of sex and comorbidity – a data linkage study

    by B. Sarraf, R. Skoien, G. Hartel, J. O'BEirne, P.J. Clark, L. Collins, B. Leggett, E.E. Powell, P.C. Valery


  • Open Access

    Gene Variants Implicated in Steatotic Liver Disease: Opportunities for Diagnostics and Therapeutics

    by Gary Huang, Daniel F. Wallace, Elizabeth E. Powell, Tony Rahman, Paul J. Clark, V. Nathan Subramaniam

    Non-alcoholic fatty liver disease (NAFLD) describes a steatotic (or fatty) liver occurring as a consequence of a combination of metabolic, environmental, and genetic factors, in the absence of significant alcohol consumption and other liver diseases. NAFLD is a spectrum of conditions. Steatosis in the absence of inflammation is relatively benign, but the disease can progress into more severe forms like non-alcoholic steatohepatitis (NASH), liver cirrhosis, and hepatocellular carcinoma. NAFLD onset and progression are complex, as it is affected by many risk factors. The interaction between genetic predisposition and other factors partially explains the large variability of NAFLD phenotype and natural history. Numerous genes and variants have been identified through large-scale genome-wide association studies (GWAS) that are associated with NAFLD and one or more subtypes of the disease. Among them, the largest effect size and most consistent association have been patatin-like phospholipase domain-containing protein 3 (PNPLA3), transmembrane 6 superfamily member 2 (TM6SF2), and membrane-bound O-acyltransferase domain containing 7 (MBOAT7) genes. Extensive in vitro and in vivo studies have been conducted on these variants to validate these associations. The focus of this review is to highlight the genetics underpinning the molecular mechanisms driving the onset and progression of NAFLD and how they could potentially be used to improve genetic-based diagnostic testing of the disease and develop personalized, targeted therapeutics.


  • Open Access

    Hepatitis C treatment outcomes for Australian First Nations Peoples: equivalent SVR rate but higher rates of loss to follow-up

    by Paul J. Clark, Patricia C. Valery, James Ward, Simone I. Strasser, Martin Weltman, Alexander Thompson, Miriam T. Levy, Barbara Leggett, Amany Zekry, Julian Rong, et al.

    Background: First Nations Peoples of Australia are disproportionally affected by hepatitis C (HCV) infection. Through a prospective study we evaluated the outcome of direct-acting antiviral (DAA) therapy among First Nations Peoples with HCV infection.Methods: Adults who initiated DAA therapy at one of 26 hospitals across Australia, 2016–2019 were included in the study. Clinical data were obtained from medical records and the Pharmaceutical and Medicare Benefits Schemes. Outcomes included sustained virologic response (SVR) and loss to follow-up (LTFU). A multivariable analysis assessed factors associated with LTFU.Results: Compared to non-Indigenous Australians (n = 3206), First Nations Peoples (n = 89) were younger (p < 0.001), morel likely to reside in most disadvantaged (p = 0.002) and in regional/remote areas (p < 0.001), and had similar liver disease severity. Medicines for mental health conditions were most commonly dispensed among First Nations Peoples (55.2% vs. 42.8%;p = 0.022). Of 2910 patients with follow-up data, both groups had high SVR rates (95.3% of First Nations Peoples vs. 93.2% of non-Indigenous patients;p = 0.51) and ‘good’ adherence (90.0% vs. 86.9%, respectively;p = 0.43). However, 28.1% of First Nations Peoples were LTFU vs. 11.2% of non-Indigenous patients (p < 0.001). Among First Nations Peoples, younger age (adj-OR = 0.93, 95% CI 0.87–0.99) and treatment initiation in 2018–2019 vs. 2016 (adj-OR = 5.14, 95% CI 1.23–21.36) predicted LTFU, while higher fibrosis score was associated with better engagement in HCV care (adj-OR = 0.71, 95% CI 0.50–0.99).Conclusions: Our data showed that First Nations Peoples have an equivalent HCV cure rate, but higher rates of LTFU. Better strategies to increase engagement of First Nations Peoples with HCV care are needed.


  • Open Access

    Liver Disease and Poor Adherence Limit Hepatitis C Cure: A Real-World Australian Treatment Cohort

    by Paul J. Clark, Patricia C. Valery, Simone I. Strasser, Martin Weltman, Alexander J. Thompson, Miriam Levy, Barbara Leggett, Amany Zekry, Julian Rong, Peter Angus, et al.

    Background and Aims In 2016, direct-acting antiviral (DAA) treatment for hepatitis C (HCV) became available through Australia’s universal health care system, with the aim of HCV elimination. We report real-world effectiveness of DAA HCV treatment in Australia from a clinically well-informed cohort, enriched for cirrhosis and prior HCV treatment. Methods 3413 patients were recruited from 26 hospital liver clinics across Australia from February 2016 to June 2020. Clinical history and sustained viral response (SVR) were obtained from medical records and data linkage to the Australian Pharmaceutical Benefits Scheme. Factors associated with SVR were assessed by multivariable logistic regression (MVR). Results At recruitment, 32.2% had cirrhosis (72.9% Child Pugh class B/C), and 19.9% were treatment experienced. Of the 2,939 with data, 93.3% confirmed SVR. 137 patients received second-line therapy. Patients with cirrhosis had lower SVR rate (88.4 vs. 95.8%; p < 0.001). On MVR, failure to achieve SVR was associated with Genotype 3 (adj-OR = 0.42, 95%CI 0.29–0.61), male gender (adj-OR = 0.49, 95%CI 0.31–0.77), fair/poor adherence (adj-OR = 0.52, 95%CI 0.28–0.94), cirrhosis (adj-OR = 0.57, 95%CI 0.36–0.88), FIB-4 > 3.25 (adj-OR = 0.52, 95%CI 0.33–0.83) and MELD score ≥ 20 (adj-OR = 0.25, 95%CI 0.08–0.80). Consistent results were seen in cirrhotic sub-analysis. Conclusions Excellent SVR rates were achieved with DAAs in this real-world cohort of patients with chronic HCV infection. More advanced liver disease and clinician impression of poor adherence were associated with HCV treatment failure. Supports to improve liver fibrosis assessment skills for non-specialist DAA prescribers in the community and to optimize patient adherence are likely to enable more effective pursuit of HCV elimination in Australia.